<i>Supporting data for</i><i> "</i><i>Modulation of IL-17 Enhances the Efficiency of Anti-PD-1 Therapy in Non-small-cell Lung Cancer"</i>

We demonstrated PD-L1 expression in EGFR and KRAS mutant and EGFR/KRAS-wildtype tumor organoids by IFN-γ or co-culture compared with tumor organoids. PD-1 action on T cells and the cytotoxicity of effector T cells through sustained CD107a, perforin and Granzyme B expression in CD8+ T cells were detected by flow cytometry after anti-PD-1 treatment. On the other hand, IL-17 concentration in NSCLC patients and non-cancer individuals was detected by ELISA. The level of IL-17 in NSCLC patients' plasma was detected by ELISA. In the tumor organoids-T cells co-culture system, we investigated the concomitant presence of IL-17 and IL-17R expression on EGFR-MT, KRAS-MTEGFR/KRAS-WT tumor organoids. IL-17R expression on CD4+ and CD8+ T cells was detected by flow cytometry. Modulation of IL-17 blockade on the efficacy of PD-1 blockade in EGFR-MT, KRAS-MT and EGFR/KRAS-WT NSCLC tumor organoids was detected by flow cytometry.